Takeda Pharmaceutical Company Limited (4502.T)
| Previous close | 4,143.00 |
| Open | 4,160.00 |
| Bid | 4,121.00 x 0 |
| Ask | 4,126.00 x 0 |
| Day's range | 4,121.00 - 4,161.00 |
| 52-week range | 3,900.00 - 4,873.00 |
| Volume | |
| Avg. volume | 4,414,406 |
| Market cap | 6.472T |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | 36.74 |
| EPS (TTM) | 112.28 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | 188.00 (4.54%) |
| Ex-dividend date | 28 Mar 2024 |
| 1y target est | 4,826.50 |
ZacksDown -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ZacksDown -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
GlobeNewswireHUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from FRESCO-2 Phase III clinical trial — HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that its partner Takeda (TSE:4502/NYSE:TAK) received notification that the Com
